Verapamil (Isoptin,Knoll;Calan,Searle)

Sandler G Clayton GA Thornicroft SG . Clinical evaluation of verapamil in angina pectoris. Br Med J 1968; 3: 224–7.

Livesley B Catley PF Campbell RC Oram S . Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1973; 1: 375–8.

Johnson SM Mauritson DR Willerson JT Hillis LD . A controlled trial of verapamil for Prinzmetal's variant angina. N Engl J Med 1981; 304: 862–6.

Rosing DR Kent KM Borer JS Seides SF Maron BJ Epstein SE . Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979; 60: 1201–7.

Singh BN Ellrodt G Peter CT . Verapamil: A review of its pharmacological properties and therapeutic use. Drugs 1978; 15: 169–97.

Ellrodt G Chew CYC Singh BN . Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation 1980; 62: 669–79.

Stone PH Antman EM Muller JE Braunwald E . Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med 1980; 93: 886–904.

Dominic JA Bourne DWA Tiong GT Kirsten EB McAllister RG . The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol 1981; 3: 25–38.

Koike Y Keiichi S Isami S Saito H . Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 1979; 24: 37–47.

Schlepper M Thormann I Schwarg F . The pharmacodynamics of orally taken verapamil and verapamil retard as judged by negative dromotropic effects. Arzneim Forsch 1975; 25: 1452–5.

Singh BN Roche AHG . Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J 1977; 94: 593–9.

Singh BN Collett JT Chew CYC . New perspectives in pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 1980; 22: 243–301.

Schomerus M Spiegelhaider B Stieren B Eichelbaum M . Physiological disposition of verapamil in man. Cardiovasc Res 1976; 10: 605–12.

Woodcock BG Rietbrock I Vohringer HF Rietbrock N . Verapamil disposition in liver disease and intensive care patients: Kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther 1981; 29: 27–34.

Keefe DL Yin-Gail Y Kates RE . Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 1981; 29: 21–6.

Yong CL Kunka RL Bates TR . Factors affecting the plasma protein binding of verapamil and norverapamil in man. Res Commun Chem Pathol Pharmacol 1980; 30: 329–30.

Strigl R Gastroph G Hege HG Doring P Mehring W . The determination of verapamil in maternal and fetal blood. Geburtshiefe Frauenheilkd 1980; 40: 496–9.

Eichelbaum M Ende M Remberg G Schomerus M Dengler HJ . The metabolism of (DL-14C) verapamil in man. Drug Metab Dispos 1979; 7: 145–8.

Neugebauer G . Comparative cardiovascular action of verapamil and its major metabolites in the anesthetized dog. Cardiovasc Res 1978; 12: 247–54.

Rinkenberger RL Prystowsky EN Heger JJ Troup PJ Jackman WM Zipes DP . Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation 1980; 62: 996–1010.

Waxman HL Myerburg RJ Appel R Sung RJ . Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann Intern Med 1981; 94: 1–6.

Sung RJ Elser B McAllister RG . Intravenous verapamil for termination of reentrant supraventricular tachycardias. Ann Intern Med 1980; 93: 682–9.

Carrasco HA Fuenmayor AP Barboza JSM Gonzalez G . Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome. Am Heart J 1978; 96: 760–71.

Gibson D Sowton E . The use of beta-adrenergic receptor blocking drugs in dysarrhythmias. Prog Cardiovasc Dis 1969; 12: 16–39.

Hartel G Hartikainen M . Comparison of verapamil and practolol in paroxysmal supraventricular tachycardia. Eur J Cardiol 1976; 4: 87–90.

Soler-Soler J Sagrista-Sauleda J Cabrera A , Effect of verapamil in infants with paroxysmal supraventricular tachycardia. Circulation 1979; 59: 876–9.

Aronow WS Landa D Plasencia G Wong R Karlsberg RP Ferlinz J . Verapamil in atrial fibrillation and atrial flutter. Clin Pharmacol Ther 1979; 26: 578–83.

Hagemeijer F . Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction. Circulation 1978; 57: 751–5.

Dominic J McAllister RG Kuo C Reddy CP Surawicz B . Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther 1979; 26: 710–4.

Khalsa A Olsson B Henriksson B . Effect of oral verapamil on ventricular irregularity in long-standing atrial fibrillation. Acta Med Scand 1979; 205: 39–47.

Klein HO Pauzner H DiSegni E David D Kaplinsky E . The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979; 139: 747–9.

Candell J Valle V Soler M Rius J . Acute intoxication with verapamil. Chest 1979; 75: 200–1.

DeFaire U Lundman T . Attempted suicide with verapamil. Eur J Cardiol 1977; 6: 195–8.

Opie LH . Calcium antagonists. Lancet 1980; 1: 806–10.

Husaini MH Kvasmeka J Ryden L Holberg S . Action of verapamil on sinus node, atrioventricular, and intraventricular conduction. Br Heart J 1973; 35: 734–7.

Physicians' prescribing information—verapamil. Whippany, NJ: Knoll Pharmaceuticals, June 1981.

Klein HO Lang R DiSegni E Kaplinsky E . Verapamil-digoxin interaction. N Engl J Med 1980; 303: 160.

Pedersen KE Dorph-Pedersen A Hvidt S Klitgaard NA Nielsen-Kudsk F . Digoxin-verapamil interaction. Clin Pharmacol Ther 1981; 30: 311–6.

Ryden L Saetre H . The haemodynamic effect of verapamil. Eur J Clin Pharmacol 1971; 3: 153–7.

Cutie MR Lordi NG . Compatibility of verapamil hydrochloride injection in commonly used large-volume parenterals. Am J Hosp Pharm 1980; 37: 675–6.

Cutie MR . Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1980; 38: 231.